Drug Profile
RG 7089
Alternative Names: R7089; RG7089Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Neuropeptide Y2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Europe
- 12 Nov 2008 Phase-I clinical trials in Type-2 diabetes mellitus in Europe (unspecified route)